Prior anti-CAFs break down the CAFs barrier and improve accumulation of docetaxel micelles in tumor

Background Abnormal expression of stromal cells and extracellular matrix in tumor stroma creates a tight barrier, leading to insufficient extravasation and penetration of therapeutic agents. Cancer-associated fibroblasts (CAFs) take on pivotal roles encouraging tumor progression.